Endoscopic GI Ablation Device (EGAD)
Contactless, uniform, depth-controlled laser ablation for Barrett's Esophagus — guided by imaging, designed for the standard endoscopy suite.
Map & Mark
Before ablate
Contactless
Uniform depth
One procedure
Multi-zone treatment
Digma Medical Ltd. is a medical technology company dedicated to transforming the treatment of gastroenterology pathologies, starting with Barrett's Esophagus (BE) — a pre-cancerous condition that may progress to esophageal adenocarcinoma, one of the most deadly forms of GI cancer.
We are developing a minimally invasive therapy, the Endoscopic Gastrointestinal Ablation Device (EGAD), that provides contactless, uniform, deep ablation guided by imaging. EGAD is designed to treat the full circumference of the esophagus or isolated patches in a single, safe, and efficient procedure — targeting mucosal tissue while protecting deeper layers such as the muscularis.
Our product consists of a console and a single-use catheter compatible with the working channel of standard gastrointestinal endoscopes. The EGAD procedure is being developed for performance in a standard GI endoscopy suite without requiring additional imaging equipment.
The EGAD procedure is currently being evaluated in clinical studies.
To learn more about our clinical program, please contact us. Contact us →
Minimally invasive LASER-based balloon-catheter delivery
The EGAD console and single-use catheter — designed for the standard GI endoscopy suite.
Single-use catheter delivered via the working channel of standard GI endoscopes.
Uniform, depth-controlled treatment without requiring full tissue contact.
Balloon system centralizes the laser with catheter anchoring for stable delivery.
Visible red guide pointer for targeting; NIR therapeutic laser for ablation.
Outpatient procedure using standard endoscopy technique — no fluoroscopy required.
Adjustable tissue interaction designed for various anatomies and treatment zones.
Global Barrett's Esophagus ablation devices market
$1.5B
Market size by 2033
CAGR 7.8%
12M+
Affected in the US
Large addressable population
200K+
New US cases/year
Growing incidence
60%
EAC share of esophageal cancer
6th most common cancer globally
Large unmet need and high recurrence rates with current therapies continue to drive demand for safer, more durable ablation solutions.
General Manager
Dr. Shlomit Chappel-Ram is an accomplished executive with over 20 years of leadership in the medical device and life sciences industries. At Digma Medical, she leads strategic operations, product development, and fundraising efforts for the company's endoscopic laser therapy platform. Prior to Digma, she held senior roles at Nano Dimension, Edwards Lifesciences, and Medinol, driving innovation from early-stage development through commercialization. Dr. Chappel-Ram holds a PhD in Chemistry (Summa Cum Laude) and an MBA in Management.
Co-founder and CTO
Ilan brings more than 25 years of experience in R&D and management in the medical device industry. In addition to co-founding Digma, he served as founder and CTO of Eximo Medical (acquired by AngioDynamics), CTO of Exalenz Bioscience Ltd. (acquired by Meridian BioScience), and CTO at Oridion Medical (acquired by Covidien). Ilan is the author of more than 60 patents and patent applications in medical technologies and electro-optics. He holds a master's degree in applied physics and the science of materials, summa cum laude, from the Hebrew University of Jerusalem.
Co-Founder
Dr. Irit Yaniv is the Founding Partner and CEO of Almeda Ventures and Managing Partner at Accelmed Ventures II, with over 25 years of experience in venture capital, pharmaceutical, and biotech industries. As a senior manager, skilled physician, and experienced board member, she combines leadership, decision-making, and business expertise. She holds an MD from Ben-Gurion University and an MBA from Tel Aviv University.
Board Chairman & Advisor
Chris Rowland is a veteran MedTech executive with 35+ years leading medical device companies from startup to exit. A President & CEO for more than 15 years, he has led organizations acquired by Covidien/Medtronic, Teleflex, and a Chinese strategic. He currently serves as Board Chairman of Endostart, EvoEndo, and Keyron Medical Technologies, and advises several early- and growth-stage ventures across endoscopy, urology, and minimally invasive surgery.
Scientific Advisory Board Member
Prof. Ohad Etzion is Director of the Department of Gastroenterology and Liver Diseases at Soroka University Medical Center. He has vast experience leading multicenter, multinational clinical studies and serves as a consultant to multiple companies in the biopharmaceutical and medical device industries.
Digma Medical is a privately held company backed by leading venture capital firms.
Reach out for clinical program inquiries, partnerships, or general information.
